NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
| CTMX Stock | USD 0.84 0.01 1.18% |
Slightly above 61% of CytomX Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding CytomX Therapeutics suggests that many traders are alarmed. CytomX Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CytomX Therapeutics' earnings reports, geopolitical events, and overall market trends.
CytomX |
Novo Nordisks diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
Read at zacks.com
 |
CytomX Therapeutics Fundamental Analysis
We analyze CytomX Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
CytomX Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
CytomX Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CytomX Therapeutics stock to make a market-neutral strategy. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics with similar companies.
Peers
CytomX Therapeutics Related Equities
| SPRO | Spero Therapeutics | 9.64 | ||||
| NXTC | NextCure | 2.60 | ||||
| ASMB | Assembly Biosciences | 0.49 | ||||
| ACHL | Achilles Therapeutics | 0.87 | ||||
| NUVB | Nuvation Bio | 1.18 | ||||
| TIL | Instil Bio | 2.10 |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.